Results 101 to 110 of about 122,145 (339)

Hydrocarbon-Stitched Peptide Agonists of Glucagon-Like Peptide-1 Receptor

ACS Chemical Biology, 2020
Glucagon-like peptide 1 (GLP-1) is a natural peptide agonist of the GLP-1 receptor (GLP-1R) found on pancreatic β-cells. Engagement of the receptor stimulates insulin release in a glucose-dependent fashion and increases β-cell mass, two ideal features for pharmacologic management of type 2 diabetes.
Gregory H. Bird, Accalia Fu, Silvia Escudero, Marina Godes, Kwadwo Opoku-Nsiah, Thomas E. Wales, Michael D. Cameron, John R. Engen, Nika N. Danial, Loren D. Walensky   +9 more
openaire   +3 more sources

Differential effects of glucagon-like peptide-1 receptor agonists on heart rate [PDF]

, 2017
While glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are known to increase heart rate (HR), it is insufficiently recognized that the extent varies greatly between the various agonists and is affected by the assessment methods employed.
A Asmar, A Asmar, A Ceriello, A Gill, A Jorsal, A Jorsal, A Plamboeck, AA Voors, AG Bertoni, Anne Lehmann, B Darpo, B Darpo, B Mendis, BM Scirica, C Perret-Guillaume, C Pyke, Christine Roy-Duval, David Owens, Denis Raccah, DJ Drucker, Francesca Lawson, GS Hillis, GS Hillis, H Linnebjerg, J Can van, J Skov, J Tillner, JA Lovshin, JJ Meier, JJ Meier, JR Ussher, K Swedberg, KB Margulies, KB Margulies, KC Ferdinand, KJ Griffioen, L Blonde, L Ryden, Lawrence Blonde, LE Robinson, LG Trahair, M Kim, M Komajda, M Lorenz, MA Nauck, MA Pfeffer, Martin Lorenz, MT Cooney, P Kumarathurai, P Sager, R Simo, Riccardo Perfetti, RR Holman, SE Inzucchi, SP Marso, T Vilsboll, X Zhou, Y Nakatani   +57 more
core   +1 more source

Connecting the dots: A narrative review of the relationship between heart failure and cognitive impairment

ESC Heart Failure, Volume 12, Issue 2, Page 1119-1131, April 2025.
Abstract Large clinical data underscore that heart failure is independently associated to an increased risk of negative cognitive outcome and dementia. Emerging evidence suggests that cerebral hypoperfusion, stemming from reduced cardiac output and vascular pathology, may contribute to the largely overlapping vascular dementia and Alzheimer's disease ...
Mauro Massussi, Maria Giulia Bellicini, Marianna Adamo, Andrea Pilotto, Marco Metra, Alessandro Padovani, Riccardo Proietti   +6 more
wiley   +1 more source

Dual Glucose-Dependent Insulinotropic Polypeptide and Glucagon-Like Peptide-1 Receptor Agonists

Endocrinology Research and Practice, 2022
Glucagon-like peptide-1 is the most potent incretin secreted from the intestinal tract. It is synthesized by L-cells in the jejunum and distal ileum of the gastrointestinal system.
Dilek Tüzün
doaj  

The Road towards Triple Agonists: Glucagon-Like Peptide 1, Glucose-Dependent Insulinotropic Polypeptide and Glucagon Receptor - An Update [PDF]

Endocrinology and Metabolism
Obesity is the fifth leading risk factor for global deaths with numbers continuing to increase worldwide. In the last 20 years, the emergence of pharmacological treatments for obesity based on gastrointestinal hormones has transformed the therapeutic ...
Agnieszka Jakubowska, Carel W. le Roux, Adie Viljoen   +2 more
doaj   +1 more source

Renoprotective mechanisms of glucagon-like peptide-1 receptor agonists

Diabetes & Metabolism
Glucagon-like peptide-1 (GLP-1) is an incretin hormone, secreted from gut endocrine cells, which acts to potentiate nutrient-induced insulin secretion. Activation of its receptor, GLP-1R, decreases glucagon secretion and gastric emptying, thereby decreasing blood glucose and body weight. It is largely through these mechanisms that Glucagon-like peptide-
Chen J, Cooper ME, Coughlan MT
openaire   +2 more sources

Effect of Oral Semaglutide Compared With Placebo and Subcutaneous Semaglutide on Glycemic Control in Patients With Type 2 Diabetes: A Randomized Clinical Trial. [PDF]

, 2017
Importance: Glucagon-like peptide-1 (GLP-1) receptor agonists are effective therapies for the treatment of type 2 diabetes and are all currently available as an injection.
Davies, Melanie, Hansen, Oluf K.H., Hartoft-Nielsen, Marie-Louise, Jabbour, Serge, Pieber, Thomas R., Rosenstock, Julio   +5 more
core   +1 more source

Semaglutide normalizes increased cardiomyocyte calcium transients in a rat model of high fat diet‐induced obesity

ESC Heart Failure, Volume 12, Issue 2, Page 1386-1397, April 2025.
Sequeira et al. reveal how the glucagon‐like peptide‐1 receptor agonist (GLP‐1‐RA) semaglutide restores cardiomyocyte function in rats subjected to a high‐fat/high‐fructose diet (HFD). Employing fluorescence‐ and patch‐clamp technology in isolated cardiac myocytes, they demonstrate that semaglutide reverses HFD‐induced activation of L‐type calcium ...
Vasco Sequeira, Julia Theisen, Katharina J. Ermer, Marie Oertel, Anton Xu, David Weissman, Katharina Ecker, Jan Dudek, Martin Fassnacht, Alexander Nickel, Michael Kohlhaas, Christoph Maack, Ulrich Dischinger   +12 more
wiley   +1 more source

Population profile and glycemic control following initiation or switch of injectable therapies in Tianjin, China: A real‐world retrospective cohort study of adults with type 2 diabetes

Journal of Diabetes Investigation
Aims To evaluate characteristics and glycemic outcomes in individuals with type 2 diabetes using injectable therapies in real‐world clinical practice in Tianjin, China.
Qiumei Zhang, Yaqing Fan, Xixi Liu, Minlu Zhang, Jiewen Zhang, Qin Du, Lei Kang, Liming Chen   +7 more
doaj   +1 more source

The GLP-1 receptor agonists exenatide and liraglutide activate Glucose transport by an AMPK-dependent mechanism [PDF]

, 2016
Additional file 2: Figure S2. Effects of EXE on Glut-4 in cultured L6 myotubes. Myotubes were stimulated with 100 nmol/l EXE for 20 min or 48 h. Panel A shows qPCR of Glut-4 mRNA.
Alberto M. Davalli, Cecilia Nigro, Claudia Miele, Francesco Andreozzi, Francesco Beguinot, Franco Folli, Gaia Chiara Mannino, Giorgio Sesti, Gregory Alexander Raciti, Teresa Procopio   +9 more
core   +3 more sources